Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지

The Korean Practice Parameter for the Treatment of Pervasive Developmental Disorders : Pharmacological Treatment

전반적 발달장애의 한국형 치료 권고안 : 약물치료

  • Cho, In-Hee (Department of Psychiatry, Gachon University of Medicine and Science) ;
  • Yoo, Han-Ik K. (Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Son, Jung-Woo (Department of Neuropsychiatry, Chungbuk National University College of Medicine) ;
  • Yoo, Hee-Jeong (Department of Psychiatry, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Koo, Young-Jin (Department of Neuropsychiatry, Eulji University College of Medicine) ;
  • Chung, Un-Sun (Department of Neuropsychiatry, Kyungpook National University College of Medicine) ;
  • Ahn, Dong-Hyun (Department of Neuropsychiatry, Hanyang University Medical School) ;
  • Ahn, Joung-Sook (Department of Psychiatry, Yonsei University Wonju College of Medicine)
  • 조인희 (가천의과대학교 정신과학교실) ;
  • 유한익 (울산대학교 의과대학 서울아산병원 정신과학교실) ;
  • 손정우 (충북대학교 의과대학 신경정신과학교실) ;
  • 유희정 (서울대학교 의과대학 분당서울대학교병원 정신과학교실) ;
  • 구영진 (을지대학교 의과대학 신경정신과학교실) ;
  • 정운선 (경북대학교 신경정신과학교실) ;
  • 안동현 (한양대학교 신경정신과학교실) ;
  • 안정숙 (연세대학교 원주의과대학 정신과학교실)
  • Published : 2007.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

The objective of this review is to establish practice parameters for pharmacological treatment of children and adolescents with pervasive developmental disorders. We performed a detailed review of the literature, including a wide range of controlled clinical trials, open trials, case reports, and side-effect profiles of related drugs. Few medications have a treatment indication for pervasive developmental disorders, and few studies with well-controlled methodology are available for evaluating treatment results. Pharmacological treatments focus on associated target symptoms because symptom reduction may improve educational and social ability and enhance quality of life. Well-controlled trials have been conducted for some SSRI(selective serotonin reuptake inhibitor) antidepressants, risperidone, and methylphenidate, and showed reduction of some target symptoms. Since the medications are not specific to autism and do not treat core symptoms of the disorder, their potential side effects should be carefully considered. Family education is necessary to give proper information on target symptoms, limitation of drug treatments, and risks.

Keywords